is semaglutide still on the shortage list An Ongoing Crisis: Raises Dual Concerns for Obesity and Diabetes Treatment Ozempic and Wegovy officially moved – GLP-1 No Longer on FDA's

10.1007/s12325-021-01710-0 6 ArodaV

"The risk of developing these severe side effects is very small, but it is important that patients and healthcare professionals are aware and alert to the associated symptoms." In the UK, the most commonly used GLP-1 therapies are Novo Nordisk's semaglutide-based Ozempic for diabetes and Wegovy for obesity, as well as Eli Lilly's Mounjaro (tirzepatide), which are all given as weekly injections

It is a documented hepatotoxic risk class, and the one gray-market semaglutide paper that actually tested vials found endotoxin in every sample they could analyze

Some also report improvements in energy levels and blood sugar stability, especially those using it for diabetes management